Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lomitapide - Novelion Therapeutics

Drug Profile

Lomitapide - Novelion Therapeutics

Alternative Names: AEGR-733; BMS-201038; JUXTAPID; Juxtapid; Lojuxta

Latest Information Update: 07 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Amryt Pharma; Novelion Therapeutics; University of Pennsylvania
  • Class Antihyperlipidaemics; Benzamides; Biphenyl compounds; Fluorenes; Piperidines; Small molecules
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type IIa
  • Registered Hypercholesterolaemia

Most Recent Events

  • 06 Feb 2019 Aegerion Pharmaceuticals enters into a marketing license agreement with Recordati Rare Diseases to commercialise lomitapide for Hyperlipoproteinaemia type IIa in Japan
  • 08 Nov 2018 Novelion Therapeutics plans to discuss proposed development plan for Hyperlipoproteinaemia type I with the US FDA
  • 17 Oct 2018 Launched for Hyperlipoproteinaemia type IIa (Adjunctive treatment) in Italy (PO) before October 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top